Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

138.90 -4.48 (-3.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Natera Presents Data at ESMO GI on its Tissue-Free Latitude™ MRD* Assay, Demonstrating Excellent Overall Performance in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Present Clinical and Economic Utility of Signatera at ESMO GI, Highlights Innovations in MRD
From Natera, Inc.
Via Business Wire
Natera Announces Medicare Coverage for Signatera™ Genome
From Natera, Inc.
Via Business Wire
SignateraTM Genome Clinical Performance Highlighted at ASCO 2025
From Natera, Inc.
Via Business Wire
Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting
From Natera, Inc.
Via Business Wire
Natera Reports First Quarter 2025 Financial Results
From Natera, Inc.
Via Business Wire
Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress
From Natera, Inc.
Via Business Wire
Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows
From Natera, Inc.
Via Business Wire
Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera
From Natera, Inc.
Via Business Wire
Natera to Report its First Quarter Results on May 8, 2025
From Natera, Inc.
Via Business Wire
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
From Natera, Inc.
Via Business Wire
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
From Natera, Inc.
Via Business Wire
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
From Natera, Inc.
Via Business Wire
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
From Natera, Inc.
Via Business Wire
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
From Natera, Inc.
Via Business Wire
Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD
From Natera, Inc.
Via Business Wire
Natera Reports Fourth Quarter and Full Year 2024 Financial Results
From Natera, Inc.
Via Business Wire
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung Cancer
From Natera, Inc.
Via Business Wire
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025
From Natera, Inc.
Via Business Wire
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma
From Natera, Inc.
Via Business Wire
Natera Announces National Commercial Coverage for its Fetal RhD NIPT
From Natera, Inc.
Via Business Wire
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
Natera to Present New Data at the 2025 ASCO GI Symposium
From Natera, Inc.
Via Business Wire
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year
From Natera, Inc.
Via Business Wire
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection
From Natera, Inc.
Via Business Wire
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
From Natera, Inc.
Via Business Wire
Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
From Natera, Inc.
Via Business Wire
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.